Physician profile
Deanne Collier
NPI 1891771689
$4,969.39
in general payments reported to CMS, 2019-2025
26 companies · $858 in 2025
The $858 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $329 · 2021: $641 · 2022: $629 · 2023: $1,063 · 2024: $867 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,718 · Education: $70.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,717.55 |
| Education | $70.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $919.99 | 2021-2025 | Opzelura |
| Pfizer INC. | $574.18 | 2019-2025 | |
| Dermavant Sciences, INC. | $466.52 | 2022-2024 | Vtama |
| Almirall LLC | $412.25 | 2019-2025 | Klisyri, Seysara |
| Sun Pharmaceutical Industries INC. | $399.81 | 2019-2025 | Winlevi |
| Arcutis Biotherapeutics, INC. | $367.64 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $339.43 | 2020-2021 | |
| Abbvie INC. | $299.56 | 2025 | |
| Galderma Laboratories, L.P. | $266.33 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| Leo Pharma INC. | $240.85 | 2019-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $156.35 | 2019-2024 | Arazlo, Jublia, Duobrii |
| Mayne Pharma Commercial LLC | $90.78 | 2019-2023 | |
| Organon LLC | $65.46 | 2025 | |
| Prugen, INC. Pharmaceuticals | $59.49 | 2019 | |
| Ethicon US, LLC | $55.55 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $40.67 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $30.31 | 2021 | |
| Lilly USA, LLC | $28.33 | 2025 | Ebglyss |
| Dusa Pharmaceuticals, INC. | $27.59 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $24.56 | 2019 | |
| Genzyme Corporation | $23.01 | 2021 | |
| Mylan Pharmaceuticals INC. | $21.12 | 2019 | |
| Promius Pharma LLC | $19.34 | 2019 | |
| Epi Health, LLC | $17.65 | 2019 | |
| Strata Skin Sciences, INC. | $13.74 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $8.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanne Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.